AnaptysBio, Inc. (NASDAQ:ANAB) major shareholder Holdings A/S Novo sold 491,294 shares of AnaptysBio stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $21.12, for a total value of $10,376,129.28. Following the sale, the insider now directly owns 2,952,527 shares in the company, valued at $62,357,370.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Holdings A/S Novo also recently made the following trade(s):

  • On Thursday, August 3rd, Holdings A/S Novo sold 70,706 shares of AnaptysBio stock. The shares were sold at an average price of $23.31, for a total value of $1,648,156.86.

AnaptysBio, Inc. (NASDAQ:ANAB) traded down 5.49% during trading on Tuesday, hitting $21.53. The company had a trading volume of 128,321 shares. The company’s 50 day moving average price is $25.09 and its 200-day moving average price is $24.56. The stock’s market capitalization is $436.39 million. AnaptysBio, Inc. has a 1-year low of $15.17 and a 1-year high of $30.71.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, May 11th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.57. On average, analysts expect that AnaptysBio, Inc. will post ($2.48) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/08/anaptysbio-inc-nasdaqanab-major-shareholder-sells-10376129-28-in-stock.html.

A number of brokerages have recently commented on ANAB. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Stifel Nicolaus lifted their price objective on AnaptysBio from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. Credit Suisse Group reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of AnaptysBio in a research note on Tuesday, April 18th. Finally, Robert W. Baird began coverage on AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $35.60.

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new stake in shares of AnaptysBio during the first quarter worth approximately $373,000. JPMorgan Chase & Co. bought a new stake in shares of AnaptysBio during the first quarter worth approximately $3,851,000. Endurant Capital Management LP bought a new stake in shares of AnaptysBio during the first quarter worth approximately $258,000. Iguana Healthcare Management LLC bought a new stake in shares of AnaptysBio during the first quarter worth approximately $1,388,000. Finally, Boxer Capital LLC bought a new stake in shares of AnaptysBio during the first quarter worth approximately $1,388,000. Institutional investors own 72.79% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.